SPY314.27+0.49 0.16%
DIA259.38+0.34 0.13%
IXIC10,400.73+56.84 0.55%

Fusion Pharmaceuticals Prices 12.5M Share IPO @$17/Share

Fusion Pharmaceuticals Inc. (NASDAQ: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the pricing of its initial public offering of 12,500,000 common shares at a public

Benzinga · -
Fusion Pharmaceuticals Inc. (NASDAQ: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the pricing of its initial public offering of 12,500,000 common shares at a public offering price of $17.00 per share. All of the shares are being offered by Fusion. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Fusion, are expected to be$212.5 million. In addition,Fusion has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 common shares at the initial public offering price. The shares are expected to begin trading on the Nasdaq Global Market onJune 26, 2020under the ticker symbol "FUSN." The offering is expected to close onJune 30, 2020, subject to the satisfaction of customary closing conditions. Morgan Stanley, Jefferies, and Cowen,are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as lead manager for the offering.